SBL
LYRA

Sargent Bickham Lagudis’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Sargent Bickham Lagudis’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2
Closed -$1K – 971
2021
Q1 		$1K Buy
+2
New +$1.25K ﹤0.01% 896

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Sargent Bickham Lagudis's LYRA Position: Q2 2021 in Review

Sargent Bickham Lagudis sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2021, closing a stake of 2 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in LYRA in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 44 funds tracked by Wall St. Rank hold LYRA as of Q2 2021.

  • Sargent Bickham Lagudis reported no remaining LYRA THERAPEUTICS INC position as of Q2 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 2 LYRA THERAPEUTICS INC shares in Q2 2021, an estimated $1K.
  • Sargent Bickham Lagudis first reported a position in LYRA THERAPEUTICS INC in Q1 2021 and held it in 1 quarter.
  • Sargent Bickham Lagudis's LYRA THERAPEUTICS INC position peaked at $1K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2021, filed 19 Jul 2021.